Skip to content
MatchScript
Menu

Head-to-head · The Match Score

ShedRx vs InstaRX

Both scored on the same six-factor Match Score. ShedRx wins this matchup with a 86 to 64 edge.

Higher Match Score

ShedRx

#4 · Grade B+

People who want an oral or sublingual option rather than weekly injections.

Visit ShedRx
VS

InstaRX

#221 · Grade C

People who want compounded GLP-1 plus peptides and sexual health on one account.

Visit InstaRX

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
84
59
Speed to Start
84
92
Formulary Match
92
66
Support Level
86
70
Flexibility
88
55
Transparency
82
46

Price, coverage & formulary

DetailShedRxInstaRX
Semaglutide$199/mo$199/mo (starting dose, compounded)
Tirzepatide$299/mo$199/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjectable only
Match Score86 · B+64 · C
Winner: ShedRx

ShedRx edges out InstaRX, 86 to 64 on the default Match Score. A weight-focused program that also offers an oral/sublingual route for the needle-averse.

InstaRX is still a fair pick if its strengths line up with yours — best for: People who want compounded GLP-1 plus peptides and sexual health on one account.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full ShedRx reviewFull InstaRX review

More head-to-heads

Or browse alternatives to ShedRx and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.